Haemophilus influenzae type b immunization in adults infected with the human immunodeficiency virus.

Authors

De Sousa dos Santos S, Lopes MH, Simonsen V, et al.

Institution

Department of Infectious and Parasitic Diseases, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, Brazil. ssigrid@hotmail.com

Source

AIDS Res Hum Retroviruses 2004 May; 20(5) :493-6.

Abstract

The purpose of this study was to assess the influence of Haemophilus influenzae type b conjugate vaccine on HIV-1 RNA level, CD4 count, and anti-Hib polysaccharide (PRP) antibody concentration. Eighty HIV-infected adults were randomized to receive Hib conjugate vaccine or not. Twenty HIV-seronegative controls were also vaccinated. Blood samples were taken before and after vaccination, with a follow-up period of 6 months. HIV infection markers and anti-PRP antibodies were monitored. There was no change in either HIV-1 viremia or CD4 count after vaccination. Immunization immunogenicity was superior in HIV-uninfected than in HIV-infected individuals (p < 0.01). Hib vaccination was safe but induced suboptimal antibody response in HIV-infected adults.

Mesh

Adult
Antibodies, Bacterial
CD4 Lymphocyte Count
Case-Control Studies
Female
HIV Infections
Haemophilus Vaccines
Humans
Male
Viral Load

Language

eng

Pub Type(s)

Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't

PubMed ID

15186523

Content Manager

Related Content

The immunogenicity of Haemophilus influenzae type b conjugate vaccines in children born to human immunodeficiency virus-infected women. Women and Infants Transmission Study Group.

Persistence of antibody responses to Haemophilus influenzae type b polysaccharide conjugate vaccine in children with vertically acquired human immunodeficiency virus infection.

Antibody response to Haemophilus influenzae type b vaccine in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus.

Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection.

Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenzae type b conjugate vaccine.

Immunity to Haemophilus influenzae type b polysaccharide capsule after vaccination with the complete series of oligosaccharide CRM197 conjugate vaccine in infants with human immunodeficiency virus infection.

The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus-infected and uninfected infants.

Immunogenicity of three Haemophilus influenzae type b protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response.